BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 13, 2006
 |  BioCentury  |  Finance

Medarex chronicles

Medarex chronicles

Medarex has been on an upward trajectory since the market bottom in early 2003. The stock has been boosted by high-profile antibody deals with Pfizer (PFE) and Bristol-Myers (BMY). M&A in the antibody space also has helped, in particular the acquisition of Abgenix by Amgen (AMGN) and the takeout of Cambridge Antibody by AstraZeneca (LSE:AZN; AZN). Weekly stock price for MEDX tracked against selected events since the company went public in June 1991. Y-axis on logarithmic scale

A. 3/3/97 - Acquires Houston Biotech for about $9.1M in stock, adding an ophthalmic program to its cancer, AIDS and autoimmune diseases programs

B. 5/6/97 - Announces...

Read the full 509 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >